Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: A multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2

Cancer Immunology Immunotherapy

Volumn 47, Issue 3, 1998, Pages 149-156

  Mantovani, Giovanni ^a   Gebbia, Vittorio ^b   Airoldi, Mario ^c   Bumma, Cesare ^c   Contu, Paolo ^a   Bianchi, Alessandro ^a   Ghiani, Massimo ^a   Dessì, Daniela ^a   Massa, Elena ^a   Curreli, Luigi ^a   Lampis, Biancarosa ^a   Lai, Paola ^a   Mulas, Carlo ^a   Testa, Antonio ^b   Proto, Ernesto ^a   Cadeddu, Gabrio ^d   Tore, Giorgio ^d  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d SS Trinit Hospital   (Italy)

Author keywords

Cisplatin; Neo adjuvant chemotherapy; Randomized phase III trial; rlL 2 immunotherapy; Squamous cell head and neck carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; RECOMBINANT INTERLEUKIN 2;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ERYTHEMA; FEMALE; HEAD AND NECK CANCER; HUMAN; IMMUNOTHERAPY; LEUKOPENIA; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 7844234373     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050515     Document Type: Article

References (39)

1. Airoldi M, Bumma C, Cortesina G, Succo G, Pedani F, De Stefani A, Bertetto O (1995) Phase II trial of cisplatin (CDDP) + 5-fluorouracil (5-FU) + IL-2 s.c. in recurrent head and neck cancer. Proc Am Soc Clin Oncol 14:303
2. Beahrs OH, Henson DE, Hutter RVP, Myers MH (1988) Manual for staging of cancer. American Joint Committee on Cancer, 3rd edn. Lippincott, Philadelphia
3. Choksi AJ, Dimery IW, Hong WK (1988) Adjuvant chemotherapy of head and neck cancer: the past, the present, the future. Semin Oncol 15:45
4. Cortesina G, De Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C, Forni G (1998) Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62:2482
5. Cortesina G, De Stefani A, Galeazzi E, Cavallo GP, Jemma C, Giovarelli M, Vai S, Forni G (1991) Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck 13:125
6. Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer N Engl J Med 324:1685
7. Dimery IW, Hong WK (1993) Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85:95
8. El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol 14:838
9. Gebbia V, Testa A, Valenza R, Zerillo G, Restivo S, Ingria F, Cannata G, Gebbia N (1993) A pilot study of vinorelbine on a weekly schedule in recurrent and or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 29:1358
10. Gebbia V, Mantovani G, Farris A, Agostara B, Desogus A, Curreli L, Moschella F, Di Gregorio C, Bajetta E, Gebbia N (1997) Vinorelbine, cisplatin and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study. Cancer 79:1394
11. Glisson BS, Hong WK (1996) Primary chemotherapy of advanced head and neck cancer. Where do we go from here? J Natl Cancer Inst 88:567
12. Head and Neck Contracts Program (1987) Adjuvant chemotherapy for advanced head and neck squamous carcinoma: final report. Cancer 60:301
13. International Union against Cancer (Hermanek P, Sobin LH, eds) (1992) TNM classification of malignant tumours, 4th edn, 2nd revision. Springer, Berlin Heidelberg New York
14. Ishikawa T, Ikawa T, Eura M, Fukiage T, Masuyama K (1989) Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2. Acta Otolaryngol (Stockh) 107:346
15. Jacobs C, Makuch R (1990) Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the Head and Neck Contracts Program. J Clin Oncol 8:838
16. Lefebvre JL, Sahmoud T. for the EORTC Head and Neck Cancer Cooperative Group (1994) Larynx preservation in hypopharynx squamous cell carcinoma: preliminary results of a randomized study (EORTC 24891). Proc Am Soc Clin Oncol 13:283
17. Mantovani G, Bianchi A, Curreli G, Ghiani M, Santona MC, Proto E, Puxeddu P (1995) Neo-adjuvant chemotherapy ± immunotherapy with s.c. IL-2 in advanced squamous cell carcinoma of the head and neck: a pilot study. Biotherapy 8:91
18. Miller AB, Hoogstraten B, Staquet M, Winkler M (1981) Reporting results of cancer treatment. Cancer 47:207
19. Murphy BA (1996) New drug therapy for squamous carcinoma of the head and neck. Curr Opin Oncol 8:221
20. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, Jirillo A, Tomio L, Fila G, Fede A, Endrizzi L, Bari M, Sampognaro E, Balli M, Gava A, Pappagallo GL, Fiorentino MV (1994) Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265
21. Pai VR, Parikh DM, Mazumdar AT, Rao RS (1993) Phase II study of high dose Ifosfamide as single agent and in combination with eisplatin in the treatment of advanced and/or recurrent squamous cell carcinoma of head and neck. Oncology 50:86
22. Sacchi M, Vitolo D, Sedlmayr P, Rabinowich H, Johnson JT, Herberman RB, Whiteside TL (1991) Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2. Int J Cancer 47:784
23. Schantz SP, Dimery I, Lippman SM, Clayman GL, Pellegrino C, Morice R (1992) A phase II study of interleukin-2 and interferon-alpha in head and neck cancer. Invest New Drugs 10:217
24. Schlappack O, Hainz A, Berghammer P, Grasl M, Kautzky M, Kment G, Dobrowsky W, Dittrich C (1993) Treatment of head and neck cancer patients (pts) with carboplatin, 5-FU, interferon alpha and interleukin-2. Proc Am Soc Clin Oncol 12:282
25. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD (1988) Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 98:1205
26. Squadrelli-Saraceno M, Rivoltini L, Cantù G, Ravagnani F, Parmiani G, Molinari R (1990) Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2. Tumori 76:566
27. Tsukuda M (1995) Neo-adjuvant chemotherapy in patients with head and neck cancer. Gan To Kagaku Ryoho 22:1905
28. Urba S, Forastiere AA, Amrein PC, Wolf GT, Zeffren J (1991) A phase II pilot study of concomitantly administered recombinant human interleukin-2 (RIL-2) and roferon-a (RIFN) in patients (PTS) with locally recurrent or metastatic head and neck cancer (H and N CA). Proc Am Soc Clin Oncol 10:A695
29. Valente G, De Stefani A, Jemma C, Giovarelli M, Geuna M, Cortesina G, Forni G, Palestro G (1990) Infiltrating leukocyte populations and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin 2. A pathologic and immunophenotypic study. Mod Pathol 3:702
30. Valone FH, Gandara DR, Deisseroth AB, Perez EA, Rayner A, Aronson FR, Luce J, Paradise C (1991) Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head neck carcinomas. J Immunother 10:207
31. Vlock DR, Snyderman CH, Johnson JT, Myers EN, Eibling DE, Rubin JS, Kirkwood JM, Dutcher JP, Adams GL (1994) Phase IB trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol 15:134
32. Vokes EE, Athanasiadis I (1996) Chemotherapy for squamous cell carcinoma of head and neck: The future is now. Ann Oncol 7:15
33. Vokes EE, Choi KE, Schilsky RL, Moran WJ, Guarnieri CM, Weichselbaum RR, Panje WR (1988) Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6:618
34. Vokes EE, Weichselbaum RR, Mick R, McEvilly JM, Haraf DJ, Panje WR (1992) Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 84:877
35. Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, Hamasaki V, Weichselbaum RR, Panje WR, Wenig B, Berezin F (1993a) Cisplatin, fluorouracil and leucovorin augmented by interferon alpha-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 11:360
36. Vokes EE, Weichselbaum RRm Lippman SM, Hong WK (1993b) Head and neck cancer. N Engl J Med 328:184
37. Wanebo HJ, Jones T, Pace R, Cantrell R, Levine P (1989) Immune restoration with interleukin-2 in patients with squamous cell carcinoma of the head and neck. Am J Surg 158:356
38. World Health Organization (1979) Handbook for reporting results of cancer treatment. No 48. WHO, Geneva
39. Yoneda K, Yamamoto T, Ueta E, Osaki T (1992) Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients. J. Clin Immunol 12:289